[
  {
    "question": "50-year-old patient, heavy smoker, hypertensive on medication, came with history of left eye visual changes & dysarthria for 10 min then resolved, asked about next?",
    "option_a": "MRI brain",
    "option_b": "CTA neck",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case describes a classic transient ischemic attack (TIA): a self\u2010limiting episode of neurological dysfunction caused by transient cerebral ischemia. Given the patient\u2019s vascular risk factors (hypertension and heavy smoking) and the nature of his symptoms (transient visual changes and dysarthria), the next step is to evaluate the potential vascular source of embolism. TIAs are typically due to temporary occlusion of a cerebral artery often from an embolus or in situ thrombosis over an atherosclerotic plaque. In patients with risk factors like atherosclerosis, an unstable plaque in the carotid artery may intermittently shed emboli leading to transient neurological deficits. The patient\u2019s symptoms\u2014transient visual changes (which may represent amaurosis fugax) and dysarthria\u2014are indicative of ischemia in areas supplied by the carotid circulation. The presence of such symptoms in a high-risk patient mandates urgent evaluation to stratify risk and prevent subsequent stroke. Initial evaluation of suspected TIA typically includes neuroimaging (CT or MRI) to rule out acute infarction, followed by vascular imaging. Differential diagnoses include migraine with aura, seizure-related transient deficits, and ocular causes. However, in a patient with vascular risk factors, evaluation of the carotids is paramount. Carotid imaging via CT angiography (CTA neck) or duplex ultrasound is used to identify significant stenosis. Management involves both diagnostic evaluation and secondary prevention. First-line evaluation includes brain imaging to exclude stroke and vascular imaging (CTA neck, carotid duplex) to evaluate for carotid stenosis. In addition, antiplatelet therapy (e.g., aspirin) and aggressive risk factor modification (smoking cessation, control of hypertension, statin therapy) are essential. In pregnant or lactating patients, alternative imaging modalities (like carotid duplex ultrasound) may be preferred to minimize radiation exposure, though CTA can be performed with proper shielding if necessary. Option A (MRI brain) is useful for detecting small infarcts but does not evaluate the carotid vasculature directly. Option B (CTA neck) is the most appropriate next step as it assesses the extracranial carotid arteries for atherosclerotic disease or dissection, which is critical in TIA workup. The other options are not provided and therefore are not considered. 1. TIA is a warning sign of potential future strokes\u2014prompt evaluation is crucial. 2. Vascular imaging (such as CTA neck) is indispensable to identify a treatable source of embolism. 3. Risk factor modification is a cornerstone of secondary prevention. Recent guidelines from the American Heart Association emphasize rapid vascular imaging in TIA patients to identify high-risk lesions and guide early intervention. Studies continue to support early carotid imaging as part of a comprehensive stroke prevention strategy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with high NIHSS then dropped down to 6 but still has dysarthria and weakness what do next?",
    "option_a": "Give t-PA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question concerns the management decision in acute ischemic stroke when there is dramatic early improvement but residual deficits persist. The key concept is that even if a patient\u2019s NIH Stroke Scale (NIHSS) improves, if disabling deficits remain, treatment with IV t-PA is still indicated. Acute ischemic stroke results from an arterial occlusion leading to brain tissue ischemia. Early reperfusion therapy (with t-PA) helps to salvage at-risk brain tissue. In some cases, spontaneous partial recanalization may occur, leading to improvement, but residual deficits (such as dysarthria and weakness) may still be significant and disabling. Despite an initial high NIHSS, the patient\u2019s improvement to an NIHSS of 6 does not eliminate the possibility of a clinically significant and disabling stroke. Dysarthria and weakness can significantly impair daily functioning. The risk of deterioration or incomplete recovery supports proceeding with reperfusion therapy in eligible patients. The diagnostic workup includes a non-contrast CT scan (to rule out hemorrhage) and clinical scoring using the NIHSS. Differential considerations include transient ischemic attack (if deficits resolve completely) versus an evolving stroke. In this case, the persistent deficits indicate a stroke that may benefit from thrombolytic therapy. According to current guidelines, IV t-PA is indicated for acute ischemic stroke within the 4.5-hour window unless contraindicated. First-line management is rapid thrombolysis with t-PA. For patients with residual disabling deficits, even after some improvement, reperfusion therapy is recommended. In pregnant patients, the use of t-PA is controversial but may be justified if benefits outweigh risks, and similarly in lactating patients, t-PA is considered relatively safe. Option A (Give t-PA) is correct because the presence of residual disabling deficits (even with an improved NIHSS of 6) qualifies the patient for thrombolytic therapy provided he is within the window and no contraindications exist. The other options (B, C, D) were not provided, making t-PA the best and only provided management option. 1. Improvement in NIHSS does not automatically preclude the use of t-PA if deficits remain disabling. 2. Even an NIHSS of 6 can represent a stroke that significantly impairs function. 3. \u2018Rapidly improving\u2019 is a relative contraindication only if the deficits are non-disabling. Recent stroke guidelines underscore that patients with \u2018rapid improvement\u2019 but residual disabling symptoms should not be excluded from thrombolysis. Updated research reinforces the benefit of t-PA in salvaging brain tissue in eligible patients, with several studies addressing the management of these borderline cases.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with stroke syndrome findings suggestive of lateral pons (patient has hearing problem)?",
    "option_a": "AICA",
    "option_b": "PICA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case centers on lateral pontine syndrome. The involvement of auditory pathways in the lateral pons is most characteristically associated with infarction of the territory supplied by the anterior inferior cerebellar artery (AICA). An infarct in the AICA territory affects the lateral pons where important structures including the cochlear nuclei are located, leading to symptoms such as hearing loss. Damage to the adjacent neural structures may also produce deficits like facial paralysis and ataxia. In patients presenting with stroke symptoms localized to the lateral pons, the presence of hearing impairment strongly points toward an AICA infarct. This helps differentiate it from other brainstem syndromes (e.g., lateral medullary syndrome from PICA infarction) which rarely present with hearing loss. Diagnosis is supported by clinical exam and confirmed with neuroimaging (CT or MRI). Differential diagnoses include lateral medullary syndrome (PICA infarct) and other brainstem pathologies; however, the notable finding of hearing loss is more specific for AICA involvement. Acute management aligns with stroke protocols \u2013 rapid evaluation, consideration of thrombolytic therapy if within the window, and supportive care. Secondary prevention includes antiplatelets, statins, and risk factor management. In pregnancy or lactation, similar stroke guidelines apply; thrombolysis can be considered if benefits outweigh risks, with careful monitoring and multidisciplinary management. Option A (AICA) is correct because hearing loss is a hallmark of lateral pontine syndrome due to AICA infarction. Option B (PICA) is incorrect because lateral medullary syndrome from PICA infarct typically spares hearing. Options C and D were not provided. 1. AICA infarcts classically present with ipsilateral hearing loss, vertigo, and facial weakness. 2. Differentiation from lateral medullary syndrome relies heavily on the presence of auditory symptoms. 3. Accurate localization aids in optimizing management strategies. Recent neuroimaging advances have improved the diagnostic accuracy of brainstem strokes. Current guidelines continue to recommend prompt reperfusion therapy for eligible patients with posterior circulation strokes, with careful attention to clinical localization.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Attached picture of a patient with Horner\u2019s (ptosis, miosis) came with thunderclap HA, ct brain and LP done within 4 hr, was normal!!",
    "option_a": "Pcom aneurysm rupture",
    "option_b": "RCVS",
    "option_c": "ICA dissection",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This clinical scenario describes a patient who presents with thunderclap headache and signs of Horner\u2019s syndrome (ptosis and miosis). These features are highly suggestive of an internal carotid artery (ICA) dissection, a known cause of such presentations. ICA dissection occurs when a tear in the arterial wall allows blood to enter and split the layers of the vessel wall, often compromising the sympathetic plexus that runs along the artery. This results in Horner\u2019s syndrome. The sudden, severe headache (\u201cthunderclap headache\u201d) is a common presenting feature. Patients with ICA dissection frequently present with a unilateral headache, neck pain, and ipsilateral Horner\u2019s syndrome. The normal CT scan and lumbar puncture (LP) help rule out subarachnoid hemorrhage, making ICA dissection the most likely diagnosis in this setting. Although the initial CT brain and LP are normal, further evaluation with CT angiography (or MR angiography) of the neck is essential to identify the dissection. Differentials include ruptured aneurysm (e.g., Pcom aneurysm rupture which typically shows hemorrhage on CT) and reversible cerebral vasoconstriction syndrome (RCVS, which usually lacks Horner\u2019s syndrome). Management of ICA dissection involves antithrombotic therapy (either antiplatelet agents or anticoagulation) to prevent thromboembolic complications. This is typically the first-line treatment. In cases where symptoms deteriorate or if there is evidence of compromised cerebral blood flow, endovascular repair may be considered. For pregnant or lactating patients, antithrombotic therapies (especially low-dose aspirin) are used with caution, considering the safety profiles and risk\u2013benefit assessments in these populations. Option A (Pcom aneurysm rupture) would generally produce subarachnoid hemorrhage with positive CT/LP findings. Option B (RCVS) usually causes thunderclap headache without the classic finding of Horner\u2019s syndrome. Option C (ICA dissection) is correct because it best explains the combination of thunderclap headache and Horner\u2019s syndrome in the context of normal CT/LP findings. 1. Horner\u2019s syndrome in the setting of a thunderclap headache is a red flag for carotid dissection. 2. Normal CT and LP do not rule out ICA dissection; vascular imaging is required. 3. Early diagnosis and treatment with antithrombotic therapy can reduce the risk of subsequent stroke. Current guidelines and recent studies continue to support the use of antithrombotic therapy as first-line management for cervical artery dissection. Advances in vascular imaging have significantly improved early detection, and updated consensus statements provide guidance on management in special populations such as pregnant and lactating patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "SAH female young patient with symptomatic PComm aneurysm next?",
    "option_a": "Clipping",
    "option_b": "Coiling",
    "option_c": "Discharge",
    "option_d": "Medical treatment",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Aneurysmal subarachnoid hemorrhage (SAH) most often results from rupture of a cerebral aneurysm. In this case, a young female with a symptomatic posterior communicating artery (PComm) aneurysm presents a scenario where the key step is to secure the aneurysm to prevent rebleeding. Two primary methods are available: surgical clipping and endovascular coiling. The rupture of an aneurysm leads to blood extravasation into the subarachnoid space, provoking a cascade of events including increased intracranial pressure, inflammation, and vasospasm due to breakdown products of blood. The PComm aneurysm\u2019s location often makes it amenable to endovascular intervention because modern coiling techniques can effectively isolate the aneurysm from the circulation with lower invasiveness. Patients with SAH typically present with a sudden, severe headache ('thunderclap headache'), along with signs of meningeal irritation and possible focal deficits depending on the hemorrhage location. Securing the aneurysm rapidly is critical to reduce the high risk of rebleeding in the acute phase. Initial diagnosis is made with a non-contrast CT scan of the head to identify hemorrhage. Following this, CT angiography or digital subtraction angiography is employed to localize and characterize the aneurysm, distinguishing it from other vascular lesions and guiding the treatment plan. Current guidelines (supported by studies such as ISAT) favor endovascular coiling for many aneurysms due to its less invasive nature and lower immediate morbidity compared to clipping. First-line treatment in a suitable aneurysm is coiling, provided the aneurysm morphology supports it. In women of child\u2010bearing age, careful attention is needed with radiation exposure and contrast use; multidisciplinary input ensures that pregnancy (or potential pregnancy) is managed appropriately. Second-line or alternative treatment is surgical clipping, which may be considered based on aneurysm anatomy or if endovascular expertise is unavailable. Option A (Clipping) is a valid treatment modality but is more invasive; Option B (Coiling) is the chosen and correct option as it is typically preferred when the aneurysm\u2019s morphology is favorable; Option C (Discharge) is inappropriate given the life\u2010threatening nature of aneurysmal SAH; Option D (Medical treatment) is inadequate since active intervention is required to prevent rebleeding. 1) Nimodipine is used in SAH for vasospasm prophylaxis. 2) Endovascular coiling is less invasive and, in suitable aneurysms, has been shown to yield better short\u2010term outcomes. 3) Multidisciplinary evaluation is essential in determining the best approach for aneurysm management. Recent updates and evidence from the International Subarachnoid Aneurysm Trial (ISAT) and subsequent studies support the use of endovascular coiling in anatomically favorable aneurysms. Advancements in endovascular technology continue to refine patient selection and improve outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "ICH case, target bp?",
    "option_a": "140/90",
    "option_b": "160/90",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In intracerebral hemorrhage (ICH), blood pressure management is critical since elevated blood pressure can contribute to hematoma expansion. The goal is to safely reduce blood pressure to minimize further bleeding while maintaining adequate cerebral perfusion. High blood pressure exerts force on the already compromised vessel walls in ICH, potentially worsening the hemorrhage. Controlling the blood pressure reduces the transmural pressure gradient across the vessel wall, thereby limiting hematoma growth. Patients with ICH often present acutely with focal neurological deficits and altered consciousness. Elevated blood pressure in these patients is common as a physiologic response, but unchecked it may lead to worsening outcomes due to hematoma expansion. CT scanning is the gold standard for identifying and characterizing ICH. Additional vascular imaging may be done to rule out underlying vascular anomalies. Differential diagnoses include ischemic stroke with hemorrhagic transformation and other mimics such as tumors or cerebral amyloid angiopathy. According to current guidelines (e.g., AHA/ASA), in patients with ICH who present with systolic blood pressures between 150-220 mm Hg, it is recommended to lower the systolic blood pressure to around 140 mm Hg. This approach minimizes hematoma expansion while avoiding the risk of cerebral hypoperfusion. In pregnant or lactating patients, careful selection of antihypertensive medications (such as labetalol or hydralazine) with proven safety profiles is important. Option A (140/90) corresponds to the common target of reducing the systolic pressure to about 140 mm Hg, which is in line with guideline recommendations. Option B (160/90) would be considered less aggressive and may not optimally prevent hematoma expansion. The other options are either missing or not applicable. 1) The INTERACT2 trial supports lowering systolic blood pressure to 140 mm Hg in ICH. 2) Avoid overly aggressive lowering to prevent cerebral hypoperfusion. 3) Early blood pressure management is crucial to limit hematoma growth. Recent trials such as INTERACT2 and ATACH-II have provided substantial evidence supporting the safe reduction of systolic BP to 140 mm Hg in ICH patients, and these findings are reflected in the most recent AHA/ASA guidelines.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient who came with 1 day history of ischemic stroke, high bp SBP 190, CT brain reported established stroke next?",
    "option_a": "Keep bp the same",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In the management of acute ischemic stroke, permissive hypertension is generally allowed in order to maintain cerebral perfusion in the ischemic penumbra. This is especially true when the patient is outside the thrombolytic window, as is the case here with an established infarct on CT. In acute ischemic stroke, the body often compensates with elevated blood pressure to improve perfusion to the ischemic brain areas. Premature reduction in blood pressure may compromise blood flow to the penumbral region, potentially enlarging the infarct size. Patients who present with ischemic stroke within the first 24 hours often have elevated BP as a compensatory mechanism. The CT scan findings of an established stroke indicate that the infarct is complete and that aggressive lowering of blood pressure might risk further hypoperfusion of regions that are still at risk. Imaging with CT is key to differentiating between ischemic stroke and hemorrhage and to identify whether the infarct is established. Clinical assessment and BP monitoring play a critical role in determining management. Current guidelines recommend not lowering blood pressure immediately in acute ischemic stroke patients who are not candidates for reperfusion therapy. Unless the blood pressure is extremely high (typically above 220/120 mm Hg), a permissive approach is advised. In patients receiving thrombolysis, a target of <185/110 mm Hg is recommended. In pregnant or lactating patients, careful blood pressure control with medication that is safe in these populations (e.g., labetalol) is advised, but the general principle of avoiding unnecessary BP reduction remains. Option A ('Keep bp the same') is correct because, in the setting of an established ischemic stroke without a thrombolytic indication, maintaining a higher blood pressure can help preserve perfusion to the penumbra. Other options that advocate for lowering BP could risk reducing cerebral blood flow and worsening ischemia. 1) Permissive hypertension is standard in acute ischemic stroke when not undergoing thrombolysis. 2) Avoid lowering BP in the first 24 hours unless extremely high. 3) The target for thrombolytic candidates is <185/110 mm Hg, but this does not apply here. Several studies have shown that early aggressive blood pressure lowering in acute ischemic stroke without thrombolysis does not improve outcomes and may be harmful. These findings have solidified the practice of permissive hypertension in these patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient k/c DM, cardiac risk factors on ASA came with right hemiplegia, has left MCA stenosis what is your next step?",
    "option_a": "Medical",
    "option_b": "endarterectomy",
    "option_c": "stenting",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The patient described has significant vascular risk factors and presents with right hemiplegia, correlating with left middle cerebral artery (MCA) stenosis. The management of intracranial stenosis, especially in the MCA, is predominantly medical since the lesions are less amenable to surgical intervention. Atherosclerotic narrowing in the MCA reduces the blood flow to the corresponding cerebral territory, predisposing to ischemia. In patients with diabetes and cardiac risk factors, atherosclerosis is progressive, making optimal medical management crucial. Right hemiplegia points to ischemia in the left MCA territory. Neuroimaging (CT/MRI and vessel imaging) confirms the presence of focal stenosis, which correlates with the patient\u2019s risk factors and clinical presentation. Diagnosis involves non-invasive imaging modalities like CT angiography or MR angiography to evaluate the degree and location of stenosis. Differential diagnoses include embolic occlusion and other causes of large-vessel ischemic stroke. Detailed vascular imaging helps differentiate intracranial stenosis from extracranial carotid disease. According to the latest guidelines and evidence (e.g., SAMMPRIS trial), aggressive medical management is the first-line treatment for intracranial atherosclerotic disease. This includes dual antiplatelet therapy (often aspirin plus clopidogrel in the acute/subacute phase), statin therapy, and strict control of risk factors such as hypertension, diabetes, and hyperlipidemia. In patients with this profile, endarterectomy is not performed on intracranial vessels, and stenting has been associated with higher complication rates. For pregnant or lactating women, antiplatelet and statin use require careful consideration, with medications chosen based on their safety profiles in these populations. Option A (Medical) is correct because medical management is the mainstay of treatment for intracranial MCA stenosis. Option B (Endarterectomy) is typically reserved for extracranial carotid stenosis and is not feasible for the MCA. Option C (Stenting) has been evaluated in trials like SAMMPRIS and found to carry a higher peri-procedural risk compared with aggressive medical therapy. Option D is not provided. 1) Intracranial atherosclerotic disease is best managed with aggressive medical therapy rather than surgical intervention. 2) The SAMMPRIS trial has significantly influenced management by favoring medical management over stenting. 3) Optimal control of vascular risk factors is essential to prevent recurrent events. Recent randomized control trials, notably SAMMPRIS, have reinforced that aggressive medical management (dual antiplatelet therapy, statins, and risk factor control) is superior to interventional strategies in reducing the risk of recurrent stroke in patients with intracranial stenosis.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of acute ischemic stroke patient\u2026 contraindication for tpa?",
    "option_a": "Bp>200",
    "option_b": "rapid improvement",
    "option_c": "PLT <150",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In acute ischemic stroke management with IV tPA, several contraindications must be considered. One of the classical exclusions listed in many exam settings is that patients whose neurological deficits are rapidly improving (\u201crapid improvement\u201d) are often not given tPA, since many of these patients may continue to improve without intervention. tPA works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving thrombi. However, the risk-benefit ratio is optimized when deficits are significant and persistent. Rapid improvement may indicate spontaneous recanalization or minor deficits, reducing the expected benefit of thrombolysis while still exposing patients to hemorrhagic risk. Although other factors such as severe uncontrolled hypertension (e.g., systolic >185 mm Hg) are absolute contraindications unless controlled, many clinical protocols have historically listed rapid improvement as an exclusion criterion. Patients presenting with acute ischemic stroke are evaluated for eligibility for tPA. A patient whose neurological deficits improve rapidly may be observed rather than treated because the potential risks (such as hemorrhagic transformation) may outweigh the marginal benefit if the deficit is already resolving. Prior to tPA administration, a full workup including noncontrast head CT (to exclude hemorrhage), blood pressure measurement, coagulation profile, and complete blood count (platelet count should be \u2265100,000/\u03bcL) is performed. The differential includes uncontrolled hypertension, bleeding diatheses, and mild strokes; each is evaluated for appropriateness for tPA use. Current guidelines recommend tPA only if the benefits exceed the risks. The earliest step is to control blood pressure if it is elevated (using IV antihypertensives to bring it below 185/110 mm Hg). In cases of rapidly improving symptoms, many centers opt for observation rather than administering tPA. Note that if the patient\u2019s residual deficits are still disabling despite some improvement, many now consider tPA administration even in the setting of improvement. In pregnant or lactating patients, extra caution is taken to balance risks, and blood pressure management is critical before any intervention. Option A (BP >200): Although high blood pressure is a contraindication if not promptly controlled (with the standard threshold being >185/110 mm Hg), such elevations are frequently managed prior to tPA administration. Option B (Rapid improvement): Traditionally a contraindication since patients with rapidly improving symptoms (often non\u2010disabling) were excluded in major tPA trials. Option C (Platelets <150): The accepted threshold for platelets is <100,000/\u03bcL; values between 100,000 and 150,000 are not considered an absolute contraindication. Thus, option B is the intended answer in many board-style questions. \u2022 Rapid improvement does not always guarantee full recovery; however, if deficits become minimal and non-disabling, tPA may be withheld.  \u2022 Blood pressure must be below 185/110 mm Hg prior to tPA, but elevations can be pharmacologically controlled before treatment. Recent research indicates that the decision to exclude patients based solely on rapid improvement should be individualized since some patients with transient improvement may worsen. Nonetheless, many exam guidelines still list rapid improvement as an exclusion criterion for tPA eligibility.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with lower extremity weakness worse upon coughing or Valsalva. MRI spine attached. What is your diagnosis?",
    "option_a": "Dural AVF",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In acute ischemic stroke management with IV tPA, several contraindications must be considered. One of the classical exclusions listed in many exam settings is that patients whose neurological deficits are rapidly improving (\u201crapid improvement\u201d) are often not given tPA, since many of these patients may continue to improve without intervention. tPA works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving thrombi. However, the risk-benefit ratio is optimized when deficits are significant and persistent. Rapid improvement may indicate spontaneous recanalization or minor deficits, reducing the expected benefit of thrombolysis while still exposing patients to hemorrhagic risk. Although other factors such as severe uncontrolled hypertension (e.g., systolic >185 mm Hg) are absolute contraindications unless controlled, many clinical protocols have historically listed rapid improvement as an exclusion criterion. Patients presenting with acute ischemic stroke are evaluated for eligibility for tPA. A patient whose neurological deficits improve rapidly may be observed rather than treated because the potential risks (such as hemorrhagic transformation) may outweigh the marginal benefit if the deficit is already resolving. Prior to tPA administration, a full workup including noncontrast head CT (to exclude hemorrhage), blood pressure measurement, coagulation profile, and complete blood count (platelet count should be \u2265100,000/\u03bcL) is performed. The differential includes uncontrolled hypertension, bleeding diatheses, and mild strokes; each is evaluated for appropriateness for tPA use. Current guidelines recommend tPA only if the benefits exceed the risks. The earliest step is to control blood pressure if it is elevated (using IV antihypertensives to bring it below 185/110 mm Hg). In cases of rapidly improving symptoms, many centers opt for observation rather than administering tPA. Note that if the patient\u2019s residual deficits are still disabling despite some improvement, many now consider tPA administration even in the setting of improvement. In pregnant or lactating patients, extra caution is taken to balance risks, and blood pressure management is critical before any intervention. Option A (BP >200): Although high blood pressure is a contraindication if not promptly controlled (with the standard threshold being >185/110 mm Hg), such elevations are frequently managed prior to tPA administration. Option B (Rapid improvement): Traditionally a contraindication since patients with rapidly improving symptoms (often non\u2010disabling) were excluded in major tPA trials. Option C (Platelets <150): The accepted threshold for platelets is <100,000/\u03bcL; values between 100,000 and 150,000 are not considered an absolute contraindication. Thus, option B is the intended answer in many board-style questions. \u2022 Rapid improvement does not always guarantee full recovery; however, if deficits become minimal and non-disabling, tPA may be withheld.  \u2022 Blood pressure must be below 185/110 mm Hg prior to tPA, but elevations can be pharmacologically controlled before treatment. Recent research indicates that the decision to exclude patients based solely on rapid improvement should be individualized since some patients with transient improvement may worsen. Nonetheless, many exam guidelines still list rapid improvement as an exclusion criterion for tPA eligibility.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of 1 day history of a patient with malignant MCA stroke next step (CT brain attached? 2/3 hypodensity without midline shift or hydrocephalus)",
    "option_a": "Hemicaniectomy",
    "option_b": "Osmotic therapy",
    "option_c": "ASA",
    "option_d": "Aspirin",
    "option_e": "Indications for hemicraniotomy",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In acute ischemic stroke management with IV tPA, several contraindications must be considered. One of the classical exclusions listed in many exam settings is that patients whose neurological deficits are rapidly improving (\u201crapid improvement\u201d) are often not given tPA, since many of these patients may continue to improve without intervention. tPA works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving thrombi. However, the risk-benefit ratio is optimized when deficits are significant and persistent. Rapid improvement may indicate spontaneous recanalization or minor deficits, reducing the expected benefit of thrombolysis while still exposing patients to hemorrhagic risk. Although other factors such as severe uncontrolled hypertension (e.g., systolic >185 mm Hg) are absolute contraindications unless controlled, many clinical protocols have historically listed rapid improvement as an exclusion criterion. Patients presenting with acute ischemic stroke are evaluated for eligibility for tPA. A patient whose neurological deficits improve rapidly may be observed rather than treated because the potential risks (such as hemorrhagic transformation) may outweigh the marginal benefit if the deficit is already resolving. Prior to tPA administration, a full workup including noncontrast head CT (to exclude hemorrhage), blood pressure measurement, coagulation profile, and complete blood count (platelet count should be \u2265100,000/\u03bcL) is performed. The differential includes uncontrolled hypertension, bleeding diatheses, and mild strokes; each is evaluated for appropriateness for tPA use. Current guidelines recommend tPA only if the benefits exceed the risks. The earliest step is to control blood pressure if it is elevated (using IV antihypertensives to bring it below 185/110 mm Hg). In cases of rapidly improving symptoms, many centers opt for observation rather than administering tPA. Note that if the patient\u2019s residual deficits are still disabling despite some improvement, many now consider tPA administration even in the setting of improvement. In pregnant or lactating patients, extra caution is taken to balance risks, and blood pressure management is critical before any intervention. Option A (BP >200): Although high blood pressure is a contraindication if not promptly controlled (with the standard threshold being >185/110 mm Hg), such elevations are frequently managed prior to tPA administration. Option B (Rapid improvement): Traditionally a contraindication since patients with rapidly improving symptoms (often non\u2010disabling) were excluded in major tPA trials. Option C (Platelets <150): The accepted threshold for platelets is <100,000/\u03bcL; values between 100,000 and 150,000 are not considered an absolute contraindication. Thus, option B is the intended answer in many board-style questions. \u2022 Rapid improvement does not always guarantee full recovery; however, if deficits become minimal and non-disabling, tPA may be withheld.  \u2022 Blood pressure must be below 185/110 mm Hg prior to tPA, but elevations can be pharmacologically controlled before treatment. Recent research indicates that the decision to exclude patients based solely on rapid improvement should be individualized since some patients with transient improvement may worsen. Nonetheless, many exam guidelines still list rapid improvement as an exclusion criterion for tPA eligibility.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with acute onset weakness and pain & temperature loss, sparing vibration? Dx?",
    "option_a": "Spinal cord infarction",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The central concept here is recognition of an acute spinal cord lesion that produces a dissociated sensory loss\u2014specifically, loss of pain and temperature sensation due to involvement of the spinothalamic tracts, while sparing the dorsal columns which mediate vibration and proprioception. This pattern is classic for anterior spinal artery syndrome, a form of spinal cord infarction. Spinal cord infarction typically results from occlusion of the anterior spinal artery, which supplies the anterior two-thirds of the spinal cord. This region includes not only the motor pathways but also the spinothalamic tracts, responsible for pain and temperature sensation. In contrast, the dorsal columns receive blood from the posterior spinal arteries, preserving vibratory and proprioceptive sensations. Patients often present acutely with weakness and a distinct pattern of sensory loss\u2014loss of pain and temperature with preserved vibration and proprioception below the level of the lesion. This presentation helps differentiate anterior spinal artery syndrome from other myelopathies, where both sensory modalities might be impaired. Key differential diagnoses include anterior spinal artery syndrome (spinal cord infarction) versus conditions such as transverse myelitis, compressive myelopathy, or a syrinx (syringomyelia); however, the acute onset favors an ischemic etiology. MRI of the spine is the investigation of choice to confirm infarction in the anterior spinal cord and to rule out other compressive or inflammatory causes. Management of spinal cord infarction is largely supportive. This includes maintaining adequate blood pressure and oxygenation to optimize spinal cord perfusion. There is no definitive acute therapy; thrombolytic therapy is not standard in this context. In pregnant and lactating patients, careful attention must be paid to the safety of hemodynamic support medications and imaging techniques (preferably MRI without contrast when possible). Rehabilitation plays a crucial role in long-term recovery. The presentation of acute onset weakness accompanied by loss of pain and temperature sensation with intact vibration points directly to an anterior cord lesion due to spinal cord infarction. Alternative possibilities like syringomyelia typically have a more insidious course and a 'cape-like' distribution of sensory loss, while inflammatory causes would not present as acutely. Acute onset dissociated sensory loss, where pain and temperature are impaired with intact proprioception and vibration, is a hallmark of anterior spinal artery syndrome. Prompt imaging is key to confirming the diagnosis and ruling out other causes. In all patients, including special populations such as pregnant or lactating individuals, a supportive management strategy is essential. Current guidelines emphasize early recognition and supportive care for spinal cord infarction. While ongoing research into neuroprotective strategies continues, treatment remains supportive and focused on rehabilitation. In managing pregnant or breastfeeding patients, clinicians should tailor supportive measures and imaging protocols to minimize fetal or neonatal risk.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Women after successful vaginal delivery complained of severe Headache, hemiparesis and her exam showed papilledema, what to do",
    "option_a": "CTV",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In postpartum women, especially after a vaginal delivery, the hypercoagulable state increases the risk for cerebral venous sinus thrombosis (CVT). CVT typically presents with severe headache, focal neurological deficits (such as hemiparesis), and signs of increased intracranial pressure (e.g., papilledema). During the postpartum period, hormonal changes and a hypercoagulable state predispose women to thrombosis. In CVT, thrombus formation in the dural venous sinuses impairs venous drainage, resulting in increased venous pressure, cerebral edema, and potential hemorrhagic venous infarcts. Recent evidence emphasizes early diagnosis to mitigate brain injury. The presentation of severe headache, hemiparesis, and papilledema in this patient is highly suspicious for CVT. Papilledema indicates raised intracranial pressure, while focal deficits (hemiparesis) suggest the presence of localized brain injury or infarction secondary to venous occlusion. The gold standard diagnostic tools include MR Venography and CT Venography (CTV). The latter is often more readily available and can quickly detect venous sinus occlusion. Differential diagnoses include intracranial hemorrhage, arterial stroke, post-dural puncture headache with neurological sequelae, and even eclampsia, which must be differentiated based on imaging and clinical history. First-line management for CVT is anticoagulation, typically with low molecular weight heparin even in the presence of small hemorrhagic infarcts. Subsequent therapies include transitioning to oral anticoagulants for long-term management. In pregnancy or lactation, LMWH is preferred due to its safety profile for both the mother and the infant. Supportive care, management of intracranial pressure, and monitoring for neurological deterioration are essential. Option A (CTV) is appropriate because CT Venography is a rapid, accessible imaging modality to evaluate the cerebral venous system. While MR Venography is also highly sensitive, CTV is a correct choice, especially in an acute setting. The other options (B, C, D) were not provided, but they likely represent less optimal or unrelated imaging techniques. 1) Always suspect CVT in postpartum women presenting with headache and neurological deficits. 2) Papilledema is a key indicator of increased intracranial pressure and should prompt urgent imaging. 3) Early diagnosis with CTV or MRV improves outcomes by enabling prompt anticoagulation. Recent guidelines from neurology and stroke associations underscore the importance of early imaging with CT or MR Venography for suspected CVT. Studies continue to support the safety and efficacy of early anticoagulation even in the presence of minor hemorrhagic changes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with a CT brain attached unilateral occipital stroke, asked about which artery? (According to picture)",
    "option_a": "PCA",
    "option_b": "SCA",
    "option_c": "PICA",
    "option_d": "MCA",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The occipital lobe is primarily supplied by the posterior cerebral artery (PCA). Infarctions in this region most commonly result from occlusion of the PCA, leading to visual deficits. An occlusion in the PCA causes ischemia in the occipital cortex. The resulting infarction typically affects the primary visual processing areas, leading to characteristic visual field deficits such as contralateral homonymous hemianopia with possible macular sparing. Current research supports the role of rapid reperfusion therapies in minimizing infarct size. Patients with a PCA stroke usually present with visual disturbances \u2013 most notably, a loss of the contralateral visual field. The CT image showing a unilateral occipital stroke is consistent with PCA territory involvement. This distinguishes it from other strokes that affect motor or sensory cortices. Imaging via CT and magnetic resonance imaging (MRI) can help identify the infarct location. Differential diagnoses include strokes in the middle cerebral artery (MCA) territory (which typically present with motor and sensory deficits), and those in the cerebellar regions (supplied by the SCA or PICA), which present with coordination issues. The management of an acute PCA stroke includes intravenous thrombolysis if the patient presents within the therapeutic window, followed by antiplatelet agents. Mechanical thrombectomy is considered in select cases based on the size and occlusion site. In pregnant or lactating women, thrombolysis may still be considered after careful risk\u2010benefit assessment, while antiplatelet management should consider safety for the fetus or neonate. Option A (PCA) is correct because the occipital lobe is vascularized by the posterior cerebral artery. Option B (SCA) and Option C (PICA) supply cerebellar regions, and Option D (MCA) supplies the lateral aspects of the cerebral hemispheres, which typically do not include the occipital lobe. 1) Occipital strokes most commonly result in visual field deficits like homonymous hemianopia. 2) Macular sparing is a classic finding in PCA strokes due to collateral blood supply. 3) Timely reperfusion therapy is pivotal in preserving visual function. Recent updates in stroke guidelines emphasize the window for thrombolysis and detail criteria for mechanical thrombectomy. Advanced imaging techniques are increasingly used to guide individualized management plans.",
    "exam_year": "2021",
    "exam_type": "Part I",
    "image_url": "page_39.png"
  },
  {
    "question": "Patient post carotid stent or endarterectomy (not sure) Came with altered level of conscious, CT attached (small Right frontal cortical hemorrhage)",
    "option_a": "hyperperfusion syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Hyperperfusion syndrome is a known complication following carotid revascularization procedures such as stenting or endarterectomy. It occurs due to impaired cerebral autoregulation in chronically hypoperfused brain regions. After carotid revascularization, the sudden restoration of blood flow can overwhelm the distal vasculature that has adapted to a lower perfusion state. The loss of autoregulation leads to excessive cerebral blood flow, which in turn can cause blood\u2013brain barrier disruption, vasogenic edema, and even small hemorrhages, as seen in the CT image (small right frontal cortical hemorrhage). Patients typically present within days following the procedure with symptoms ranging from headache and altered mental status to seizures. In this case, the altered level of consciousness and CT findings are consistent with hyperperfusion syndrome. Diagnosis is primarily clinical, supported by imaging findings. Differential diagnoses include embolic stroke, reperfusion injury, and hemorrhagic transformation of an ischemic infarct. A detailed review of the procedural history and blood pressure control is essential. The cornerstone of management is strict blood pressure control using IV antihypertensives (e.g., labetalol, nicardipine). In addition, supportive care and neurological monitoring are key. For patients who are pregnant or lactating, antihypertensive choices should be guided by safety profiles (e.g., labetalol is generally considered safe during pregnancy). Early recognition and aggressive blood pressure management are critical to prevent further neurological deterioration. Option A (hyperperfusion syndrome) is correct given the clinical context of recent carotid intervention, altered mental status, and the imaging findings of a small cortical hemorrhage. Other options, which were not provided, likely pertain to alternative causes of post-procedural complications but do not fit the described presentation. 1) Post-carotid revascularization, any sudden neurological deterioration should raise suspicion for hyperperfusion syndrome. 2) Strict blood pressure control is essential in the immediate postoperative period to minimize the risk of reperfusion injury. 3) Early imaging is key to differentiating between hyperperfusion syndrome and embolic events. Recent studies highlight the importance of individualized blood pressure targets post-revascularization and reinforce early detection protocols for hyperperfusion syndrome. Updated guidelines recommend the use of IV antihypertensive agents with a favorable safety profile in sensitive populations including pregnant women.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly female brought to ER with \u2193 level of consciousness. Unknown history. Her labs showed INR of 3. Brain CT attached. What is the best next step?",
    "option_a": "vitamin K",
    "option_b": "PCC",
    "option_c": "idarucizumab",
    "option_d": "FFP",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In patients with intracranial hemorrhage associated with anticoagulation therapy, immediate reversal of the coagulopathy is the primary goal. Elevated INR suggests a warfarin-related bleed, and prompt reversal is imperative. Warfarin acts by inhibiting vitamin K-dependent clotting factors (II, VII, IX, and X). An elevated INR indicates that the clotting cascade is impaired, thereby predisposing to bleeding. Prothrombin complex concentrate (PCC) rapidly supplies the deficient clotting factors, offering faster normalization of coagulation compared to vitamin K alone. The elderly female with a decreased level of consciousness, an INR of 3, and a brain CT revealing hemorrhage is most consistent with warfarin-associated intracranial hemorrhage. In such emergencies, immediate correction of the INR is crucial to prevent hematoma expansion and further neurological decline. Diagnosing warfarin-associated intracranial hemorrhage involves a combination of clinical evaluation and imaging studies. Differential diagnoses include hemorrhage from other causes such as amyloid angiopathy or traumatic brain injury. A careful review of the medication history and laboratory values (INR) is essential. The first-line management in warfarin-related ICH involves rapid reversal of anticoagulation. The current guidelines favor four-factor prothrombin complex concentrate (PCC) due to its rapid onset of action. Vitamin K (typically 10 mg IV) should be administered concurrently to ensure sustained reversal, as its effect takes several hours. Although Fresh Frozen Plasma (FFP) is an option, it is generally less preferred because of slower correction, risk of volume overload, and preparation delays. In pregnancy or lactation, vitamin K is considered safe; however, the use of PCC should be carefully weighed as data are more limited in these populations, though the life\u2010threatening nature of hemorrhage necessitates rapid intervention. Option A (vitamin K) is important but inadequate as a monotherapy in an emergency because its effect is delayed. Option B (PCC) is correct because it rapidly corrects the coagulopathy, which is critical in the setting of intracranial hemorrhage. Option C (idarucizumab) is an antidote for dabigatran, not warfarin. Option D (FFP) is a viable alternative but is less favored compared to PCC in terms of speed and efficacy. 1) In warfarin-associated ICH, rapid reversal of anticoagulation is critical; PCC is preferred over FFP due to its speed and efficiency. 2) Always administer vitamin K alongside PCC to maintain reversal of coagulopathy. 3) Always consider the type of anticoagulant when selecting the reversal agent (e.g., idarucizumab is specific for dabigatran). Recent guidelines and studies from stroke and neurocritical care societies emphasize the urgent use of four-factor PCC for the management of warfarin-associated intracranial hemorrhage. Ongoing research continues to refine protocols to minimize hematoma expansion and improve outcomes, with a growing body of evidence supporting PCC over FFP due to faster and more reliable correction of INR.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_2.png"
  },
  {
    "question": "57 years old male, DM, HTN, DLP, smoker, admitted under stroke with left sided weakness and facial asymmetry. Brain CT: right capsular infarction. Brain CTA: significant intracranial ICA stenosis. What is the best management?",
    "option_a": "medical therapy",
    "option_b": "ICA stenting",
    "option_c": "ICA endarterectomy",
    "option_d": "craniotomy",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case focuses on a patient with an acute ischemic stroke secondary to intracranial atherosclerotic disease. Intracranial ICA stenosis (as opposed to extracranial disease) is best managed medically rather than with surgical or endovascular interventions. Risk factors such as diabetes, hypertension, dyslipidemia, and smoking contribute to atherosclerotic plaque formation within the intracranial vessels. The plaque can narrow the lumen of the artery, reducing cerebral blood flow and leading to infarction, as seen in the right capsular region in this patient. The patient\u2019s presentation with left\u2010sided weakness and facial asymmetry correlates with an infarction in the right basal ganglia/capsular region. The brain CT confirms an established infarct while the CTA reveals significant stenosis of the intracranial ICA, which is the likely culprit lesion. Standard evaluation includes non\u2010contrast CT to rule out hemorrhage and CT angiography (CTA) to visualize the vascular anatomy. Differential diagnoses include small vessel lacunar infarcts due to chronic hypertension versus embolic strokes from other sources; however, the CTA findings of significant focal stenosis point to a large vessel etiology. According to current guidelines (e.g., SAMMPRIS trial), the first\u2010line management for patients with intracranial stenosis is aggressive medical therapy. This includes antiplatelet therapy (often dual therapy initially), high\u2010dose statins, and rigorous risk factor modification (blood pressure control, glycemic control, lipid management, smoking cessation). In pregnancy and lactation, medications must be chosen carefully \u2013 for instance, aspirin and certain statins have specific guidelines regarding use; risk\u2013benefit assessments are crucial when managing cardiovascular risk factors in pregnant or breastfeeding patients. A: Medical therapy \u2013 Correct. B: ICA stenting \u2013 Typically considered for extracranial lesions and has a high periprocedural risk in intracranial disease. C: ICA endarterectomy \u2013 Also reserved for extracranial carotid stenosis. D: Craniotomy \u2013 Not indicated for ischemic stroke due to atherosclerotic disease. 1. Intracranial atherosclerotic disease is managed conservatively with aggressive medical therapy. 2. Risk factor modification is essential to prevent recurrence. 3. Interventional approaches are generally reserved for refractory cases. Recent trials (SAMMPRIS and VISSIT) have demonstrated that optimal medical therapy is superior to interventional procedures in patients with intracranial atherosclerotic disease. Guidelines continue to emphasize intensive control of vascular risk factors and the use of antiplatelet/antithrombotic therapy as the mainstay of treatment.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_2.png"
  },
  {
    "question": "36 years old female referred to neurology clinic for issues with forgetting the events. She has chronic migraine headache and had suffered stroke in the past. Her father died at age of 65 with dementia. Brain MRI: subcortical WM changes likely microvascular lacunes. DX?",
    "option_a": "Moyamoya",
    "option_b": "MELAS",
    "option_c": "CADASIL",
    "option_d": "Susac disease",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case focuses on a patient with an acute ischemic stroke secondary to intracranial atherosclerotic disease. Intracranial ICA stenosis (as opposed to extracranial disease) is best managed medically rather than with surgical or endovascular interventions. Risk factors such as diabetes, hypertension, dyslipidemia, and smoking contribute to atherosclerotic plaque formation within the intracranial vessels. The plaque can narrow the lumen of the artery, reducing cerebral blood flow and leading to infarction, as seen in the right capsular region in this patient. The patient\u2019s presentation with left\u2010sided weakness and facial asymmetry correlates with an infarction in the right basal ganglia/capsular region. The brain CT confirms an established infarct while the CTA reveals significant stenosis of the intracranial ICA, which is the likely culprit lesion. Standard evaluation includes non\u2010contrast CT to rule out hemorrhage and CT angiography (CTA) to visualize the vascular anatomy. Differential diagnoses include small vessel lacunar infarcts due to chronic hypertension versus embolic strokes from other sources; however, the CTA findings of significant focal stenosis point to a large vessel etiology. According to current guidelines (e.g., SAMMPRIS trial), the first\u2010line management for patients with intracranial stenosis is aggressive medical therapy. This includes antiplatelet therapy (often dual therapy initially), high\u2010dose statins, and rigorous risk factor modification (blood pressure control, glycemic control, lipid management, smoking cessation). In pregnancy and lactation, medications must be chosen carefully \u2013 for instance, aspirin and certain statins have specific guidelines regarding use; risk\u2013benefit assessments are crucial when managing cardiovascular risk factors in pregnant or breastfeeding patients. A: Medical therapy \u2013 Correct. B: ICA stenting \u2013 Typically considered for extracranial lesions and has a high periprocedural risk in intracranial disease. C: ICA endarterectomy \u2013 Also reserved for extracranial carotid stenosis. D: Craniotomy \u2013 Not indicated for ischemic stroke due to atherosclerotic disease. 1. Intracranial atherosclerotic disease is managed conservatively with aggressive medical therapy. 2. Risk factor modification is essential to prevent recurrence. 3. Interventional approaches are generally reserved for refractory cases. Recent trials (SAMMPRIS and VISSIT) have demonstrated that optimal medical therapy is superior to interventional procedures in patients with intracranial atherosclerotic disease. Guidelines continue to emphasize intensive control of vascular risk factors and the use of antiplatelet/antithrombotic therapy as the mainstay of treatment.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_2.png"
  },
  {
    "question": "Case scenario of patient admitted with subarachnoid hemorrhage. After 2 days he was lethargic, BP 104/52, serum Na 123, \u2191 urine Na and urine osmolality. What is the best next step in management?",
    "option_a": "fluid restriction",
    "option_b": "fluid hydration",
    "option_c": "mannitol",
    "option_d": "oral Na tablet",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case focuses on a patient with an acute ischemic stroke secondary to intracranial atherosclerotic disease. Intracranial ICA stenosis (as opposed to extracranial disease) is best managed medically rather than with surgical or endovascular interventions. Risk factors such as diabetes, hypertension, dyslipidemia, and smoking contribute to atherosclerotic plaque formation within the intracranial vessels. The plaque can narrow the lumen of the artery, reducing cerebral blood flow and leading to infarction, as seen in the right capsular region in this patient. The patient\u2019s presentation with left\u2010sided weakness and facial asymmetry correlates with an infarction in the right basal ganglia/capsular region. The brain CT confirms an established infarct while the CTA reveals significant stenosis of the intracranial ICA, which is the likely culprit lesion. Standard evaluation includes non\u2010contrast CT to rule out hemorrhage and CT angiography (CTA) to visualize the vascular anatomy. Differential diagnoses include small vessel lacunar infarcts due to chronic hypertension versus embolic strokes from other sources; however, the CTA findings of significant focal stenosis point to a large vessel etiology. According to current guidelines (e.g., SAMMPRIS trial), the first\u2010line management for patients with intracranial stenosis is aggressive medical therapy. This includes antiplatelet therapy (often dual therapy initially), high\u2010dose statins, and rigorous risk factor modification (blood pressure control, glycemic control, lipid management, smoking cessation). In pregnancy and lactation, medications must be chosen carefully \u2013 for instance, aspirin and certain statins have specific guidelines regarding use; risk\u2013benefit assessments are crucial when managing cardiovascular risk factors in pregnant or breastfeeding patients. A: Medical therapy \u2013 Correct. B: ICA stenting \u2013 Typically considered for extracranial lesions and has a high periprocedural risk in intracranial disease. C: ICA endarterectomy \u2013 Also reserved for extracranial carotid stenosis. D: Craniotomy \u2013 Not indicated for ischemic stroke due to atherosclerotic disease. 1. Intracranial atherosclerotic disease is managed conservatively with aggressive medical therapy. 2. Risk factor modification is essential to prevent recurrence. 3. Interventional approaches are generally reserved for refractory cases. Recent trials (SAMMPRIS and VISSIT) have demonstrated that optimal medical therapy is superior to interventional procedures in patients with intracranial atherosclerotic disease. Guidelines continue to emphasize intensive control of vascular risk factors and the use of antiplatelet/antithrombotic therapy as the mainstay of treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Young girl with congenital heart disease presented with fever and right sided weakness. She has signs of stroke on examination. What is the best diagnostic test?",
    "option_a": "Blood culture",
    "option_b": "Brain CT",
    "option_c": "Contrasted brain CT",
    "option_d": "LP",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In an acute stroke scenario, rapid neuroimaging is critical. A noncontrast CT scan is the standard initial test to rapidly differentiate between ischemic and hemorrhagic stroke, which is essential for guiding emergent management. In a young patient with congenital heart disease and fever, septic embolism from possible infective endocarditis is a concern, but the immediate priority is to evaluate the brain for stroke. Patients with congenital heart disease are at increased risk for infective endocarditis. Vegetations on the valves can embolize, causing septic emboli that lead to ischemic infarcts (and sometimes hemorrhagic conversion) in the brain. Identification of such infarcts is best achieved initially through brain imaging. The patient\u2019s presentation with fever and right-sided weakness suggests an embolic stroke, potentially from infective endocarditis. While the fever urges evaluation for an infectious source (with blood cultures and echocardiography), the neurological deficits require immediate brain imaging to determine the nature of the stroke. The initial evaluation of stroke involves a noncontrast CT scan of the brain to rapidly rule out hemorrhage and confirm ischemic stroke. Differential diagnoses include septic embolic stroke, primary hemorrhagic stroke, brain abscess, and other central nervous system infections. Blood cultures, while crucial for diagnosing infective endocarditis, do not address the immediate need to characterize the stroke. According to current stroke guidelines, the rapid assessment of stroke via a noncontrast brain CT scan is paramount to determine therapeutic options, including potential thrombolysis. In cases where infective endocarditis is suspected, adjunctive tests such as blood cultures and echocardiography are performed subsequently. In pregnancy or lactation, noncontrast CT can be performed with appropriate fetal shielding, as it minimizes radiation exposure and is still considered the imaging modality of choice in the acute setting. Option A (Blood culture) is critical for diagnosing the underlying infective cause but is not the best test to evaluate acute neurological deficits. Option D (Lumbar puncture) is contraindicated in the setting of stroke due to the risk of herniation if intracranial pressure is elevated. Option C (Contrasted brain CT) is not the first-line imaging modality since the use of contrast can obscure the distinction between hemorrhage and ischemic areas in the acute stroke setting. Option B (Brain CT), understood as noncontrast CT, is the appropriate and immediate test for stroke evaluation. \u2022 In the acute evaluation of stroke, always prioritize a noncontrast head CT to differentiate hemorrhagic from ischemic stroke quickly. \u2022 In patients with congenital heart disease presenting with fever and stroke signs, septic emboli secondary to infective endocarditis should be suspected. \u2022 While blood cultures and echocardiography are essential for diagnosing infective endocarditis, they follow the urgent imaging required to manage acute neurological deficits. Guidelines from the American Heart Association (AHA) and the American Stroke Association consistently recommend noncontrast CT as the first-line imaging modality in suspected stroke cases due to its speed, accessibility, and ability to reliably detect hemorrhage. Recent studies reinforce that even when infective endocarditis is in the differential, immediate brain imaging is essential for stroke management and is not altered by the need for subsequent infectious work-up.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]